Howard Marks Alvotech Transaction History

Oaktree Capital Management LP

$3.32 Billion
Q1 2025

A detailed history of Howard Marks (Oaktree Capital Management LP) transactions in Alvotech stock. As of the latest transaction made, Oaktree Capital Management LP holds 1,868,483 shares of ALVO stock, worth $21.4 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares

1,868,483

Previous 1,925,705 2.97%

Holding current value

$21.4 Million

Previous $25.4 Million 28.92%

% of portfolio

0.54%

Previous 0.65%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$9.55 - $13.52 $546,470 - $773,641	-57,222 Reduced 2.97%	1,868,483 $18.1 Million
Q4 2024 Feb 12, 2025	SELL	$11.28 - $13.2 $6.84 Million - $8 Million	-606,322 Reduced 23.95%	1,925,705 $25.4 Million
Q2 2024 Aug 13, 2024	SELL	$11.4 - $14.51 $4.19 Million - $5.33 Million	-367,174 Reduced 12.66%	2,532,027 $30.8 Million
Q1 2024 May 14, 2024	SELL	$11.36 - $17.27 $29 Million - $44.1 Million	-2,551,695 Reduced 46.81%	2,899,201 $35.4 Million
Q4 2023 Feb 13, 2024	BUY	$8.55 - $11.48 $3.48 Million - $4.68 Million	407,391 Added 8.08%	5,450,896 $62.6 Million
Q3 2023 Nov 13, 2023	SELL	$8.12 - $10.07 $13.9 Million - $17.3 Million	-1,715,655 Reduced 25.38%	5,043,505 $46 Million
Q2 2023 Aug 11, 2023	SELL	$6.9 - $13.85 $41.4 Million - $83.1 Million	-6,003,473 Reduced 47.04%	6,759,160 $52.3 Million
Q1 2023 Aug 25, 2023	BUY	$10.01 - $14.03 $10 Million - $14.1 Million	1,003,473 Added 14.85%	7,762,633 $100 Million
Q1 2023 May 15, 2023	BUY	$10.01 - $14.03 $64.3 Million - $90.1 Million	6,423,973 Added 101.35%	12,762,633 $165 Million
Q2 2022 Aug 15, 2022	BUY	$8.21 - $11.19 $52 Million - $70.9 Million	6,338,660 New	6,338,660 $52 Million

Others Institutions Holding ALVO

# of Institutions

Shares Held

15.8M

Call Options Held

Put Options Held

View Full List

About Alvotech

Ticker ALVO
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 248,650,000
Market Cap $2.85B
Description
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...

More about ALVO

Track Howard Marks's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oaktree Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Oaktree Capital Management LP and Howard Marks with notifications on news.

Account